Omni Bio Pharmaceutical’s recombinant Fc-AAT development program is targeted for advancement into clinical trials in 2014/2015.
Nov 26, 2013
Omni Bio Announces Notice of Allowance for New Use Patent
Nov 22, 2013
Zack's Small-Cap Research analysts conclude, "(Omni Bio) is a $10 million company that is potentially sitting on a multi-hundred million dollar product".
Nov 20, 2013
Omni Bio Announces Reduction in Inflammatory Myocardial Injury With Its Lead Recombinant Molecule
Nov 6, 2013
Omni Bio Announces U.S. Patent Action for Its Recombinant Alpha-1 Antitrypsin Molecule
Oct 23, 2013
Diabetes Hope Continues With AAT Therapy
Oct 2, 2013
Type 1 Diabetes Overview
Sep 9, 2013
Overview of Omni Bio Pharmaceutical - September 2013
Jul 22, 2013
Omni Bio Pharmaceutical Appoints Ms. Sandra Wrobel as New Director
Jul 10, 2013
Omni Bio Announces Support for Clinical Trial of Graft vs Host Disease
Jun 3, 2013
Zack's Small-Cap Research Initiates Coverage of Omni Bio
Apr 11, 2013
Zack's Small-Cap Research Releases Analyst Report on Omni Bio
Read All News
Omni Bio is conducting research on a series of novel and highly competitive recombinant forms of AAT.
OmniBio Pharmaceutical, Inc.5350 S. Roslyn Street, Suite 430Greenwood Village, CO 80111(720) 488-4754 (Corporate & Investor Inquiries)
Copyright 2013 Omni Bio Pharmaceutical, Inc.